Volumetric Biotechnologies has announced its moving its HQ to the East End Maker Hub. Image courtesy of East End Maker Hub

The East End Maker Hub has landed perhaps its most intriguing tenant thus far — a Houston startup that makes 3D-printed human organs.

Volumetric Biotechnologies Inc. has leased 11,200 square feet at the East End Maker Hub to serve as its headquarters and manufacturing center. Jordan Miller, co-founder of Volumetric, says one of the benefits of being located at the hub will be access to a cleanroom operated by Alchemy Industrial, a 3D manufacturer of medical devices. Earlier this year, Houston-based Alchemy leased more than 5,400 square feet at the East End hub.

Volumetric will occupy space in the first phase of the 307,000-square-foot project East End Maker Hub. That phase of the $37 million project is set to open soon. The startup's current 5,000-square-foot headquarters is at 7505 Fannin St., near the Woman's Hospital of Texas and south of the Texas Medical Center.

Miller says Volumetric's new home will help it "maintain and accelerate our already breakneck progress." Volumetric's 12 biological, chemical, mechanical, and electrical engineers focus on producing human organs and tissues like the liver, kidney, pancreas, lung, and heart using a mix of medical-grade plastics and human cells.

"We're straining to scale our company as fast as our team is inventing and progressing our technologies. It's an absolutely wonderful problem to have," Miller says.

Volumetric hopes to commercialize its 3D-printed organs in 2021. Founded in 2018, Volumetric is a privately held spin-out of Rice University's Department of Bioengineering. It has received $1.8 million in funding, according to Crunchbase. Investors include Silicon Valley-based Sand Hill Angels, and the Springfield, Virginia-based Methuselah Foundation and Methuselah Fund.

Local Realtor Mike Pittman, a development associate with Pearland-based project partner Urban Partnerships Community Development Corp., recruited Volumetric to the hub. He says he's also working with a distillery, a coffee roaster, and a medical gown manufacturer on leasing space there.

The first phase of the East End Maker Hub is set to open soon. Image courtesy of East End Maker Hub

Once the East End Maker Hub opens, Houston's East End District will be home to the largest maker hub in Texas and one of the largest such facilities in the U.S. Being built in three phases on a 21-acre site at 6501 Navigation Blvd., the East End Maker Hub aims to create an environment that gives members of the community access to trade skills and career opportunities, and to provide businesses a place for innovation and manufacturing. The hub's second and third phases are on track to be finished in 2021.

The soon-to-open first phase will feature "white box" suites, ranging in size from 420 square feet to 20,000 square feet, that cater to three sectors:

  • Innovation (robotics, 3D printing, and R&D)
  • Crafting (ceramics, fine woodworking, and screen printing)
  • Light fabrication (food production).

Aside from Alchemy, tenants recently lined up for the hub include Houston-based Waste Management Inc., whose R&D team will occupy more than 3,500 square feet, and Houston-based construction technology company Rugged Robotics Inc., which is renting 1,700 square feet.

"We're not the place for software companies, but our innovation area is the place for hardware companies — those that are into drones, robotics, 3D printing," Pittman says.

The project's hardware innovation element could boost Houston's manufacturing economy, he says. A recent analysis by the Smartest Dollar website found that 7.5 percent of the Houston metro area's workforce is employed in manufacturing. From 1999 to 2019, the number of manufacturing jobs in Houston grew by just 1.9 percent.

So far, the nonprofit TXRX Labs makerspace is the hub's largest tenant, having signed a lease for 65,000 square feet in the first phase. TXRX Labs and Urban Partnerships Community Development teamed up to develop the hub. TXRX contributed $1.25 million in equity, and Urban Partnerships Community Development raised $35.75 million in capital.

Houston-based Stewart Builders is the general contractor for the East End Maker Hub, and Houston-based Method Architecture is the architect of record.

Aside from supplying room for businesses and nonprofits to grow, the hub seeks to provide training and jobs for local residents. Pittman says the hub — located within a tax-advantaged Opportunity Zone — encourages its tenants to hire people who live within a three-mile radius.

"You don't have to go and get a Ph.D. in nuclear science for these jobs to be able to attain really good wages for your family," he says.

Phases two and three of the hub are expected in 2021. Image courtesy of East End Maker Hub

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston clean hydrogen startup to pilot tech with O&G co.

stay gold

Gold H2, a Houston-based producer of clean hydrogen, is teaming up with a major U.S.-based oil and gas company as the first step in launching a 12-month series of pilot projects.

The tentative agreement with the unnamed oil and gas company kicks off the availability of the startup’s Black 2 Gold microbial technology. The technology underpins the startup’s biotech process for converting crude oil into proprietary Gold Hydrogen.

The cleantech startup plans to sign up several oil and gas companies for the pilot program. Gold H2 says it’s been in discussions with companies in North America, Latin America, India, Eastern Europe and the Middle East.

The pilot program is aimed at demonstrating how Gold H2’s technology can transform old oil wells into hydrogen-generating assets. Gold H2, a spinout of Houston-based biotech company Cemvita, says the technology is capable of producing hydrogen that’s cheaper and cleaner than ever before.

“This business model will reshape the traditional oil and gas industry landscape by further accelerating the clean energy transition and creating new economic opportunities in areas that were previously dismissed as unviable,” Gold H2 says in a news release.

The start of the Black 2 Gold demonstrations follows the recent hiring of oil and gas industry veteran Prabhdeep Singh Sekhon as CEO.

“With the proliferation of AI, growth of data centers, and a national boom in industrial manufacturing underway, affordable … carbon-free energy is more paramount than ever,” says Rayyan Islam, co-founder and general partner at venture capital firm 8090 Industries, an investor in Gold H2. “We’re investing in Gold H2, as we know they’ll play a pivotal role in unleashing a new dawn for energy abundance in partnership with the oil industry.”

------

This article originally ran on EnergyCapital.

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes an e-commerce startup founder, an industrial biologist, and a cellular scientist.

Omair Tariq, co-founder and CEO of Cart.com

Omair Tariq of Cart.com joins the Houston Innovators Podcast to share his confidence in Houston as the right place to scale his unicorn. Photo via Cart.com

Houston-based Cart.com, which operates a multichannel commerce platform, has secured $105 million in debt refinancing from investment manager BlackRock.

The debt refinancing follows a recent $25 million series C extension round, bringing Cart.com’s series C total to $85 million. The scaleup’s valuation now stands at $1.2 billion, making it one of the few $1 billion-plus “unicorns” in the Houston area.

Cart.com was co-founded by CEO Omair Tariq in October 2020. Read more.

Nádia Skorupa Parachin, vice president of industrial biotechnology at Cemvita

Nádia Skorupa Parachin joined Cemvita as vice president of industrial biotechnology. Photo courtesy of Cemvita

Houston-based biotech company Cemvita recently tapped two executives to help commercialize its sustainable fuel made from carbon waste.

Nádia Skorupa Parachin came aboard as vice president of industrial biotechnology, and Phil Garcia was promoted to vice president of commercialization.

Parachin most recently oversaw several projects at Boston-based biotech company Ginkjo Bioworks. She previously co-founded Brazilian biotech startup Integra Bioprocessos. Read more.

Han Xiao, associate professor of chemistry at Rice University

The funds were awarded to Han Xiao, a chemist at Rice University.

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories. Xiao will use the five-year grant to advance his work on noncanonical amino acids.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement. Read more.

Houston chemist lands $2M NIH grant for cancer treatment research

future of cellular health

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories.

Xiao will use the five-year grant to develop noncanonical amino acids (ncAAs) with diverse properties to help build proteins, according to a statement from Rice. He and his team will then use the ncAAs to explore the vivo sensors for enzymes involved in posttranslational modifications (PTMs), which play a role in the development of cancers and neurological disorders. Additionally, the team will look to develop a way to detect these enzymes in living organisms in real-time rather than in a lab.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement.

According to Rice, these developments could have major implications for the way diseases are treated, specifically for epigenetic inhibitors that are used to treat cancer.

Xiao helped lead the charge to launch Rice's new Synthesis X Center this spring. The center, which was born out of informal meetings between Xio's lab and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine, aims to improve cancer outcomes by turning fundamental research into clinical applications.

They will build upon annual retreats, in which investigators can share unpublished findings, and also plan to host a national conference, the first slated for this fall titled "Synthetic Innovations Towards a Cure for Cancer.”